AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Irinotecan
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT01050777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal meglumine antimoniate
Description: Liposomal form of meglumine antimoniate
Study NCT01050777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Paromomycin
Description: Liposomal form of 10% Paromomycin
Study NCT01050777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00787007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose
Study NCT00787007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, oral, single dose
Study NCT01476930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cupping and serkangabin syrup
Description: wet cupping serkangabin syrup
Study NCT01149785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
Study NCT01149785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
Study NCT04940312 — intervention group
Intervention type: BEHAVIORAL
Intervention: App-based physical activity coaching
Description: Individualized app-based coaching via a smartphone
Study NCT04940312 — intervention group
Intervention type: BEHAVIORAL
Intervention: No Intervention: Observational Cohort
Description: no Intervention
Study NCT01149785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
Study NCT04940312 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention Group 1
Description: pedometer-based tracking of physical activity
Study NCT04009434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Clipping
Description: Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
Study NCT04009434 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI
Description: Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
Study NCT04009434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
Study NCT02603003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JinFuKang
Description: po.tid.30ml
Study NCT03353051 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study NCT00152230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: to receive oral uracil-tegafur 400 mg square meter for one year
Study NCT00152230 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
Study NCT03605056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
Study NCT03605056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
Study NCT03605056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40mg weekly, will be administered orally or intravenously
Study NCT02885675 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: sample no more than 3ml
Study NCT02603003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: According to the individual patient's condition
Study NCT02603003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: According to the individual patient's condition
Study NCT02603003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: According to the individual patient's condition
Study NCT02603003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: According to the individual patient's condition
Study NCT00571064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil HCl
Description: One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
Study NCT02529709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Protein Condition
Description: The participants will be fed a high-protein meal
Study NCT02529709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Monounsaturated Fat Condition
Description: The participants will be fed a high-monounsaturated fat meal
Study NCT03525639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
Study NCT02161783 — intervention group
Intervention type: DRUG
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
Study NCT02161783 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
Study NCT02161783 — intervention group
Intervention type: RADIATION
Intervention: Total Body Irradiation
Description: TBI 200cGy in a single fraction on day -1 from transplant.
Study NCT02161783 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hematopoietic stem cell infusion
Description: Hematopoietic stem cell infusion given on day 0.
Study NCT00489307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg PO (by mouth) twice daily x 14 days
Study NCT00489307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg PO (by mouth) twice daily x 14 days
Study NCT00489307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO twice daily x 14 days
Study NCT02992366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: implant placement
Study NCT02992366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: implant placement
Study NCT02111694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bottle Type
Description: Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
Study NCT01073657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported Education
Description: Rehabilitation counseling using peers to achieve educational goals
Study NCT01073657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Peer Support
Description: Matched peer support for any personal goal other than education
Study NCT04945252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signpost caries
Description: Identify carious lesion according to ICCMS visual criteria
Study NCT01502696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2b
Description: 3µg/kg weekly injections
Study NCT04074603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The needle-free jet injector
Description: Continuous insulin therapy for 2 weeks
Study NCT04074603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional insulin pen
Description: Continuous insulin therapy for 2 weeks
Study NCT00104910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Study NCT00104910 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00104910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT00104910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04329741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week basic dog obedience training course
Description: The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
Study NCT02971904 — intervention group
Intervention type: OTHER
Intervention: human milk collection
Study NCT00189514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
Study NCT00189514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
Study NCT03868800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SDM-DC
Description: The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
Study NCT03990688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study NCT03990688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study NCT01973400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Palm-Oil derived Vitamin E, tocotrienol
Study NCT01973400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00714272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1
Description: 6 treatments. One per week during the first six consecutive weeks.
Study NCT00714272 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with a sham device, EXcorLab box 1.2
Description: 6 sham treatments. One treatment per week during the first six consecutive weeks.
Study NCT03372421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Story
Description: A short story written in the third person about what it's like to attend an assessment for ASD.
Study NCT03372421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Information
Description: Information the host site currently sends out to patients informing them about what to expect from the assessment
Study NCT05880030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 10000 UI
Study NCT05880030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sunflower oil
Study NCT02102828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extended compression
Description: Home use of extended compression therapy and aspirin
Study NCT02102828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: standard therapy of aspirin
Study NCT03097159 — intervention group
Intervention type: PROCEDURE
Intervention: Costoclavicular block
Description: Group C for costoclavicular block Group S for supraclavicular block
Study NCT03168087 — intervention group
Intervention type: OTHER
Intervention: Plasmalyte-148
Description: Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
Study NCT03461809 — intervention group
Intervention type: OTHER
Intervention: Ocular acupuncture
Description: Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
Study NCT02603029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
Study NCT02603029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Belinal cream
Description: Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
Study NCT04602000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
Study NCT04602000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
Study NCT04602000 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
Study NCT04602000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
Study NCT04602000 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
Study NCT02000271 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal packing
Study NCT02000271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No vaginal packing
Study NCT01069640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
Study NCT01374789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GemCis + Panitumumab
Description: Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
Study NCT01476930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional migraine drug treatment
Description: nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
Study NCT01046188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge Questionnaire
Description: Administered before and after teaching intervention
Study NCT01046188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Questionnaire
Description: Administered before and after teaching intervention
Study NCT01046188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perceived Stress Scale
Description: Administered before and after teaching intervention
Study NCT01046188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perceived Stress Scale
Description: Administered before and after teaching intervention
Study NCT01046188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction questionnaire
Description: Administered after the intervention and at study completion
Study NCT01374789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GemCis
Description: Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Cisplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Epirubicin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT03668418 — intervention group
Intervention type: DRUG
Intervention: Nab paclitaxel
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study NCT02982603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qinggongshoutao Bolus
Description: Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
Study NCT02982603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract 761
Description: Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
Study NCT02982603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
Study NCT03133065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of HCV with oral direct acting antiviral therapy
Description: A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
Study NCT00247221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI/Family Check-up
Description: The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
Study NCT00247221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI only
Description: An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
Study NCT03182543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango pulp beverage
Description: The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect.
Study NCT03182543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango pulp and peel beverage
Description: The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect.
Study NCT03182543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control beverage
Description: The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect.
Study NCT02048280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAVA level
Description: Peak inspiratory pressure will be measured at each NAVA level
Study NCT02048280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAVA level
Description: Increase NAVA level every 3 minutes
Study NCT02436369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low fat yogurt enriched with flaxseed
Description: daily intake of low fat yogurt enriched with flaxseed for 8 weeks
Study NCT02436369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low fat yogurt
Description: daily intake of low fat yogurt for 8 weeks